Metavia Inc. · NASDAQ:MTVA

Metavia — Corporate Update (January 2025)

16 slides from Metavia's corporate update, Jan 10, 2025

  1. Slide 1: DA-1241 Phase 2a Topline Data

    December 2023 NASDAQ: NRBO 1 Jan 2025 NASDAQ: MTVA DA-1241 Phase 2a Topline Data MASH-TAG 2025

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the us

  3. Slide 3: Compelling Investment Opportunity Targeting Obesity and MASH

    3 Compelling Investment Opportunity Targeting Obesity and MASH with a Pipeline of Next Generation Therapeutics ▪ Aiming to increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones • DA-1726 (GLP1R/GCGR dual agonist) ✓ Ongoing Phase 1 trial for the treatment of obesity ✓ Part

  4. Slide 4: DA-1241: Orally Available, Potential First-in-Class GPR119 Agonist for MASH

    December 2023 NASDAQ: NRBO 4 DA-1241 Orally Available, Potential First-in-Class GPR119 Agonist for the Treatment of MASH

  5. Slide 5: DA-1241 Mode of Action

    5 • DA-1241 is a synthetic drug that binds to GPR119 expressed on the cell surface of liver cells, immune cells (Kupfer cells, macrophages, monocytes), and hepatic astrocytes. • Multiple effects are expected by direct action on representative cells involved in pathogenesis. Fatty Liver Inflammation

  6. Slide 6: DA-1241 Phase 2a: Clinical Study Design

    DA-1241 Phase 2a: Clinical Study Design

  7. Slide 7: DA-1241 Phase 2a: Clinical Study

    7 DA-1241 Phase 2a: Clinical Study A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, PHASE 2A CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DA-1241 IN SUBJECTS WITH PRESUMED NON-ALCOHOLIC STEATOHEPATITIS (NASH) Objective • Part 1: To explore the efficacy (change from bas

  8. Slide 8: DA-1241 Phase 2a: Top-Line Results

    DA-1241 Phase 2a: Top-Line Results

  9. Slide 9: Primary Efficacy Endpoint

    9 Phase 2a Top-line Results Primary Efficacy Endpoint Placebo (N=23) 95% CI DA-1241 50mg (N=12) 95% CI DA-1241 100mg (N=22) 95% CI DA-1241 100mg + Sita 100mg (N=34) 95% CI Baseline Mean 68.4 65.8 57.2 63.2 Week 16 LS Mean -4.70 (-14.05, 4.65) -16.81 (-29.72, -3.89)* -18.09 (-27.67, -8.52)* -8.24 (-1

  10. Slide 10: Primary Efficacy Endpoint: LS Mean ALT

    10 Phase 2a Top-line Results Primary Efficacy Endpoint LS Mean ALT Changes from Baseline (U/L) -4.7 -16.81 -18.09 -8.24 -20 -18 -16 -14 -12 -10 -8 -6 -4 -2 0 ALT CFB @ W16 (U/L) * 68.4 65.8 57.2 63.2 p < 0.05 vs. placebo * p < 0.051 vs. placebo * -4.7 -16.81 -18.09 -8.24 -23 -18 -13 -8 -3 2 PBO 50mg

  11. Slide 11: Select Secondary Efficacy Endpoint

    11 Phase 2a Top-line Results Select Secondary Efficacy Endpoint * Confidence interval excludes 0, suggesting a statistically meaningful difference. LS Mean CAP, VCTE, FAST score Changes from Baseline at Week 16 Placebo (N=23) 95% CI DA-1241 50mg (N=12) 95% CI DA-1241 100mg (N=22) 95% CI DA-1241 100m

  12. Slide 12: Select Secondary Efficacy Endpoint: CAP, VCTE, FAST

    12 Phase 2a Top-line Results Select Secondary Efficacy Endpoint p < 0.05 vs. placebo * LS Mean CAP, VCTE, FAST score Changes from Baseline at Week 16 -2.32 -8.94 -24.32 -20.62 -30 -25 -20 -15 -10 -5 0 PBO 50mg 100mg Combi CAP Score CFB (dB/m) Week 16 0.29 -1.4 0 -1.45 -1.6 -1.4 -1.2 -1 -0.8 -0.6 -0.

  13. Slide 13: Select Secondary Efficacy Endpoint: HbA1c

    13 Phase 2a Top-line Results Select Secondary Efficacy Endpoint * Confidence interval excludes 0, suggesting a statistically meaningful difference. LS Mean HbA1C Changes from Baseline at Week 16 (%) Placebo (N=23) 95% CI DA-1241 50mg (N=12) 95% CI DA-1241 100mg (N=22) 95% CI DA-1241 100mg + Sita 100

  14. Slide 14: Select Secondary Efficacy Endpoint: HbA1c Chart

    14 Phase 2a Top-line Results Select Secondary Efficacy Endpoint p < 0.05 vs. placebo * LS Mean HbA1C Changes from Baseline at Week 16 (%) 0.1 -0.24 -0.48 -0.52 -0.6 -0.5 -0.4 -0.3 -0.2 -0.1 0 0.1 0.2 PBO 50mg 100mg Combi HbA1c CFB (%) Week 16 * * 6.78 6.58 7.01 6.51

  15. Slide 15: Safety Assessment

    15 Phase 2a Top-line Results Safety Assessment Overall TEAE Summary N (%) Placebo (N=32) DA-1241 50mg (N=14) DA-1241 100mg (N=26) DA-1241 100mg + Sitagliptin 100mg (N=36) Subjects with any Treatment Related AE Mild Moderate Severe 9 ( 28.1%) 8 ( 25.0%) 1 ( 3.1%) 0 4 ( 28.6%) 4 ( 28.6%) 0 0 9 ( 34.6%

  16. Slide 16: Thank You! Investor Contacts

    December 2023 NASDAQ: NRBO 16 Thank You! Investor Contacts: Rx Communications Group Michael Miller +1 917.633.6086 mmiller@rxir.com MetaVia Marshall Woodworth +1 919.749.8748 marshall.woodworth@metaviatx.com

MetaVia — Corporate Update (January 2025) on 6ix